# EDGAR Filing Document

**Accession Number:** 0001726822
**File Stem:** 0001829126-23-002000
**Filing Date:** 2023-3
**Character Count:** 7978
**Document Hash:** 2861e6cb1bcd07107076846e679cabee
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001829126-23-002000.hdr.sgml**: 20230313

**ACCESSION NUMBER**: 0001829126-23-002000

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20230313

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230313

**DATE AS OF CHANGE**: 20230313

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Soul Biotechnology Corp
- **CENTRAL INDEX KEY:** 0001726822
- **STANDARD INDUSTRIAL CLASSIFICATION:** MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
- **IRS NUMBER:** 823155323
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-56213
- **FILM NUMBER:** 23726472

**BUSINESS ADDRESS:**
- **STREET 1:** 36 FOURTH AVE. N
- **CITY:** SASKATCHEWAN
- **STATE:** A9
- **ZIP:** S3N 2V7
- **BUSINESS PHONE:** (516) 544-2812

**MAIL ADDRESS:**
- **STREET 1:** 36 FOURTH AVE. N
- **CITY:** SASKATCHEWAN
- **STATE:** A9
- **ZIP:** S3N 2V7

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Adorbs Inc.
- **DATE OF NAME CHANGE:** 20180102

?xml version="1.0" encoding="utf-8"?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549** 

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

Date of Report (date of earliest event reported): <u>March 13, 2023</u>

 ****

**<u>SOUL BIOTECHNOLOGY CORPORATION</u>**

(Exact Name of Registrant as Specified in its Charter)

---

| | | |
|:---|:---|:---|
| **Nevada** | **000-56213** | **82-3155323** |
| (State of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |

---

---

| | |
|:---|:---|
| **36 Fourth Ave. N, Saskatchewan, Canada** | **S3N 2V7** |
| (Address of principal executive offices) | (Zip Code) |

---

**<u>(516) 544-2812</u>**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act: None

Securities registered pursuant to Section 12(g) of the Act:

---

| | |
|:---|:---|
| Title of Each Class | Name of Each Exchange On Which Registered |
| Common Stock, $0.001 par value per share | **N/A** |

---

***Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.***

On March 13, 2023, the sole existing director and officer resigned immediately. Accordingly, David Lazar, serving as a director and an officer, ceased to be the President, Chief Executive Officer, Chief Financial Officer, and as a Member of the Board of Directors of the Company. Also on March 13, 2023, Rachel Martinuik consented to the new CEO, CFO, Treasurer, and a Member of the Board of Directors of the Company and Nichol Martinuik consented to act as the new President, Secretary, and a Member of the Board of Directors of the Company.

Rachel Martinuik, 47, CEO and Chair of the board of MySpray, has been part of MySpray from inception. In her previous role as Chief Operating Officer, her responsibilities included the oversight of MySpray's resources and oversees budgetary expenditures. A large part of her role was to build relationships with members of the supply chain, production labs, fulfillment, and logistic teams that all operate for MySpray remotely across Canada. Outside of MySpray, Rachel was appointed by the honorable Brad Wall to a board position for Saskatchewan Opportunities Corporation (SOCO), where she served three terms, from 2015-2021. SOCO operates under the registered business name of Innovation Place a Saskatchewan Crown Corporation. Innovation Place owns and operates technology parks adjacent to the province's universities in Saskatoon and Regina, which provides a home for 3,800 tech jobs across 150 different companies in well over 1 million square feet of managed indoor space. In 2018 Rachel earned the ICD.D designation from the Institute of Corporate Directors. Rachel is a graduate from the University of Regina with a Bachelor of Human Justice. Her education in board management and social justice provides the awareness to keep the company mindful of the personal, corporate, and social responsibility we occupy.

Nichol Martinuik, 47, President & Founder of MySpray, has been in health sciences, traditional medicine, and the natural health industry since 1997, gaining clinical experience in pain management, disease prevention, and therapeutic health solutions. He is a seasoned doctor of natural medicine (homeopathy), registered massage therapist, and natural health researcher. Nichol is the President and Founder of MySpray Therapeutics Inc., and HMTC - Homeopathic Medical & Therapy Clinic, and is registered with the Natural Health Practitioners of Canada and the Saskatchewan Association of Doctors of Natural Medicine.

**Item 9.01 Financial Statements and Exhibits.** 

(d) Exhibits.

[99.1](soulbiotechno_ex99-1.htm) [DIRECTORS RESOLUTIONS, dated March 13, 2023.](soulbiotechno_ex99-1.htm)

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

March 13, 2023

---

| | |
|:---|:---|
| **SOUL BIOTECHNOLOGY CORPORATION** | **SOUL BIOTECHNOLOGY CORPORATION** |
| By: | */s/ Rachel Martinuik* |
| Name: | Rachel Martinuik |
| Title: | CEO |

---

## Exhibit 99.1

**Exhibit 99.1**

**DIRECTORS RESOLUTIONS**

**OF**

**<u>SOUL BIOTECHNOLOGY CORPORATION</u>**

**(the "Company")**

**WHEREAS:**

A. David
 Lazar has consented to step down as Chief Executive Officer, Chief Financial Officer, Treasurer,
 Secretary and remain as a Member of the Board of Directors of the Company.

B. Rachel
 Martinuik has consented to act as the new CEO, CFO, Treasurer, and a Member of the Board
 of Directors of the Company.

C. Nichol
 Martinuik has consented to act as the new President, Secretary, and a Member of the Board
 of Directors of the Company.

**BE IT RESOLVED THAT:**

D. David
 Lazar stepped down as Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary
 and as a Member of the Board of Directors of the Company.

E. Rachel
 Martinuik shall act as the new CEO, CFO, Treasurer, and a Member of the Board of Directors
 of the Company.

F. Nichol
 Martinuik shall act as the new President, Secretary, and a Member of the Board of Directors
 of the Company.

Effective date: March 13, 2023

---

| |
|:---|
| /*s/ David Lazar* |
| David Lazar |
| /*s/ Rachel Martinuik* |
| Rachel Martinuik |
| */s/ Nichol Martinuik* |
| Nichol Martinuik |

---